Company Filing History:
Years Active: 2025
Title: Innovations in Cancer Treatment by Mitchell Bigelow
Introduction
Mitchell Bigelow is an accomplished inventor based in Cambridge, MA. He has made significant contributions to the field of cancer treatment through his innovative work on multi-specific binding proteins. His research focuses on developing therapeutic methods that target and kill human cancer cells.
Latest Patents
Bigelow holds a patent for "Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use." This patent describes multi-specific binding proteins that effectively bind to and eliminate cancer cells expressing B-cell maturation antigen (BCMA). The proteins exhibit high potency and maximum lysis of target cells compared to traditional anti-BCMA monoclonal antibodies. This innovation has the potential to enhance cancer treatment options significantly.
Career Highlights
Mitchell Bigelow is currently associated with Dragonfly Therapeutics, Inc., where he continues to advance his research in cancer therapeutics. His work is pivotal in developing new pharmaceutical compositions and therapeutic methods that can improve patient outcomes in cancer treatment.
Collaborations
Bigelow collaborates with notable colleagues, including Gregory P. Chang and Ann F. Cheung. Their combined expertise contributes to the innovative research and development efforts at Dragonfly Therapeutics.
Conclusion
Mitchell Bigelow's contributions to cancer treatment through his patented innovations highlight the importance of research in developing effective therapies. His work exemplifies the potential of multi-specific binding proteins in the fight against cancer.